Ocular Therapeutix Company Profile (NASDAQ:OCUL)

About Ocular Therapeutix

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company's product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company's lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCUL
  • CUSIP:
Key Metrics:
  • Previous Close: $6.88
  • 50 Day Moving Average: $6.83
  • 200 Day Moving Average: $8.11
  • 52-Week Range: $4.04 - $17.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.79
  • P/E Growth: 0.00
  • Market Cap: $170.52M
  • Outstanding Shares: 24,821,000
  • Beta: 0.96
Profitability:
  • Net Margins: -2,519.61%
  • Return on Equity: -52.44%
  • Return on Assets: -42.34%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 13.26%
  • Quick Ratio: 13.23%
Additional Links:
Companies Related to Ocular Therapeutix:

Analyst Ratings

Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.96 (224.85% upside)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
DateFirmActionRatingPrice TargetDetails
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 -> $5.84View Rating Details
7/26/2016BTIG ResearchReiterated RatingBuy$18.00View Rating Details
6/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/7/2016Morgan StanleyReiterated RatingOverweight$17.00 -> $16.00View Rating Details
4/10/2016Royal Bank Of CanadaReiterated RatingOutperform$48.00View Rating Details
8/5/2015NomuraInitiated CoverageBuy$46.00View Rating Details
3/11/2015Oppenheimer Holdings Inc.Boost Price TargetOutperform$42.00 -> $49.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)ViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)ViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)ViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.50 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
Current Year EPS Consensus Estimate: $-1.87 EPS
Next Year EPS Consensus Estimate: $-2.42 EPS

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocular Therapeutix (NASDAQ:OCUL)
Insider Ownership Percentage: 30.60%
Institutional Ownership Percentage: 78.45%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
DateHeadline
News IconNew report: Global ocular pain pipeline 2016 market key companies analysis (NASDAQ:OCUL)
www.whatech.com - September 27 at 6:27 PM
News IconOcular Therapeutix, Inc. (NASDAQ:OCUL) earnings reaction history - The Independent Republic (NASDAQ:OCUL)
theindependentrepublic.com - September 23 at 11:16 AM
News IconOcular Therapeutix Inc (OCUL) PT Lowered to $16.00 at Morgan Stanley - DailyQuint (NASDAQ:OCUL)
dailyquint.com - September 21 at 6:10 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Ocular Therapeutix, Infinity Pharma, Lpath, and Idera Pharma - PR Newswire (press release) (NASDAQ:OCUL)
www.prnewswire.com - September 19 at 6:32 PM
News IconResearch Reports Initiation on Biotech Stocks -- Ocular Therapeutix, Infinity Pharma, Lpath, and Idera Pharma (NASDAQ:OCUL)
www.kait8.com - September 19 at 11:03 AM
News IconIMANE Announces Lineup of Speakers at its Annual Gala, to Elect President and New Committee (NASDAQ:OCUL)
indianewengland.com - September 14 at 6:39 PM
News IconOcular Therapeutix, Inc. Pipeline Reviews and Clinical Trail Assessment 2016- Market Share, and Forecasts - Medgadget (blog) (NASDAQ:OCUL)
www.medgadget.com - September 14 at 10:49 AM
capitalcube.com logoETF’s with exposure to Ocular Therapeutix, Inc. : September 13, 2016 (NASDAQ:OCUL)
www.capitalcube.com - September 13 at 11:26 AM
News IconEarnings Analysis & Update for Ocular Therapeutix, Inc. (NASDAQ:OCUL)? - Frisco Fastball (NASDAQ:OCUL)
friscofastball.com - September 8 at 10:22 AM
News IconBiotech news that matter for investors: Ocular Therapeutix (NASDAQ ... - The Voice Registrar (NASDAQ:OCUL)
voiceregistrar.com - September 8 at 10:22 AM
News IconGlobal Spoil Detection-Based Smart Label Market 2016: Fish, Meat, Vegetables, Dairy Products (NASDAQ:OCUL)
www.medgadget.com - September 7 at 6:42 PM
News IconIntraday Active Biotech Stocks News: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Ocular Therapeutix, Inc ... - The Voice Registrar (NASDAQ:OCUL)
voiceregistrar.com - September 6 at 6:43 PM
News IconStock Down in Trading Session: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Post News (NASDAQ:OCUL)
www.kentuckypostnews.com - September 1 at 6:31 PM
News IconActive biotech company shares in the news: Ocular Therapeutix, Inc. (NASDAQ:OCUL), Arena Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:OCUL)
voiceregistrar.com - September 1 at 6:31 PM
4-traders.com logoOcular Therapeutix : trade; to Participate in the Morgan Stanley Global Healthcare Conference (NASDAQ:OCUL)
www.4-traders.com - September 1 at 9:43 AM
finance.yahoo.com logoOcular Therapeutix™ to Participate in the Morgan Stanley Global Healthcare Conference (NASDAQ:OCUL)
finance.yahoo.com - September 1 at 9:43 AM
News IconOcular Therapeutix, Inc. (NASDAQ:OCUL) topped earnings-per-share estimates 66% of the time - The Independent Republic (NASDAQ:OCUL)
theindependentrepublic.com - August 30 at 6:32 PM
capitalcube.com logoETF’s with exposure to Ocular Therapeutix, Inc. : August 29, 2016 (NASDAQ:OCUL)
www.capitalcube.com - August 29 at 6:23 PM
News IconOcular Therapeutix Relocates to Bedford For Expansion (NASDAQ:OCUL)
www.bankerandtradesman.com - August 23 at 6:46 PM
News IconGlaucoma Treatment Market Analysis and Forecast to 2019 (NASDAQ:OCUL)
www.medgadget.com - August 21 at 10:40 AM
News IconTrading the Biotech News: Eleven Biotherapeutics (NASDAQ:EBIO), Ocular Therapeutix (NASDAQ:OCUL) - The Voice Registrar (NASDAQ:OCUL)
voiceregistrar.com - August 20 at 10:40 AM
finance.yahoo.com logoOCULAR THERAPEUTIX, INC Financials (NASDAQ:OCUL)
finance.yahoo.com - August 17 at 6:52 PM
News IconInvestor News: Ocular Therapeutix Inc (NASDAQ:OCUL) under Investigation over potential Wrongdoing (NASDAQ:OCUL)
www.groundreport.com - August 17 at 9:40 AM
capitalcube.com logoETF’s with exposure to Ocular Therapeutix, Inc. : August 16, 2016 (NASDAQ:OCUL)
www.capitalcube.com - August 16 at 6:45 PM
News IconWill Ocular Therapeutix Inc. (NASDAQ: OCUL)'s DEXTENZA Make It To Market? - Scibility Media (NASDAQ:OCUL)
scibilitymedia.com - August 16 at 9:53 AM
capitalcube.com logoOcular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:OCUL)
www.capitalcube.com - August 15 at 6:56 PM
News IconTrading the Biotech News: Seres Therapeutics, Inc. (NASDAQ:MCRB), Ocular Therapeutix, Inc. (NASDAQ:OCUL) - The Voice Registrar (NASDAQ:OCUL)
voiceregistrar.com - August 15 at 8:49 AM
schaeffersresearch.com logoAnalyst Upgrades: Apple Inc., Chesapeake Energy Corporation, and Ocular Therapeutix Inc (NASDAQ:OCUL)
www.schaeffersresearch.com - August 11 at 7:04 PM
finance.yahoo.com logoEdited Transcript of OCUL earnings conference call or presentation 9-Aug-16 12:30pm GMT (NASDAQ:OCUL)
finance.yahoo.com - August 10 at 9:42 AM
fortune.com logoAnalyst Views That Are Worth Watching: Sarepta Therapeutics Inc ... - Review Fortune (NASDAQ:OCUL)
reviewfortune.com - August 9 at 6:52 PM
streetupdates.com logoStocks inside Analysts Limelight: Gilead Sciences, Inc. (NASDAQ:GILD) , Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Street Updates (NASDAQ:OCUL)
www.streetupdates.com - August 9 at 6:52 PM
biz.yahoo.com logoOcular Therapeutix Inc Earnings Call (Q2 2016) (NASDAQ:OCUL)
biz.yahoo.com - August 9 at 9:49 AM
streetinsider.com logoForm 10-Q OCULAR THERAPEUTIX, INC For: Jun 30 (NASDAQ:OCUL)
www.streetinsider.com - August 9 at 9:49 AM
reuters.com logoBRIEF-Ocular Therapeutix Q2 loss per share $0.46 (NASDAQ:OCUL)
www.reuters.com - August 9 at 9:49 AM
tmcnet.com logoOcular Therapeutix™ Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:OCUL)
www.tmcnet.com - August 9 at 9:49 AM
twst.com logoOcular Therapeutix Inc.: Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:OCUL)
www.twst.com - August 9 at 9:49 AM
sg.finance.yahoo.com logoOcular Therapeutix reports 2Q loss (NASDAQ:OCUL)
sg.finance.yahoo.com - August 9 at 9:49 AM
biz.yahoo.com logoOcular Therapeutix Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:OCUL)
biz.yahoo.com - August 9 at 9:49 AM
News IconMarket Movers: Bristol-Myers Squibb Co (NYSE:BMY), Ocular ... - NYSE Journal (press release) (NASDAQ:OCUL)
stockznews.com - August 6 at 9:26 AM
businesswire.com logoOcular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society ... - Business Wire (press release) (NASDAQ:OCUL)
www.businesswire.com - August 5 at 9:40 AM
finance.yahoo.com logoOcular Therapeutix™ Provides Update on NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain - Yahoo Finance (NASDAQ:OCUL)
finance.yahoo.com - August 5 at 9:40 AM
News IconStock's Earnings Analysis Report: Brixmor Property Group Inc. (NYSE:BRX), Ocular Therapeutix, Inc. (NASDAQ:OCUL) - News Oracle (NASDAQ:OCUL)
www.newsoracle.com - August 5 at 9:40 AM
News IconHome Biotech Stocks Ocular Therapeutix, Inc. | $OCUL Stock | Shares Spike Up On News... - TickerTV News (press release) (NASDAQ:OCUL)
ticker.tv - August 5 at 9:40 AM
thestreet.com logoThese 7 Stocks Under $10 Are Making Big Moves Higher (NASDAQ:OCUL)
www.thestreet.com - August 5 at 9:40 AM
thestreet.com logoOcular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns (NASDAQ:OCUL)
www.thestreet.com - August 4 at 7:00 PM
finance.yahoo.com logoWhy is Ocular Therapeutics (OCUL) Surging 36% Today? (NASDAQ:OCUL)
finance.yahoo.com - August 4 at 7:00 PM
streetinsider.com logoOcular Therapeutix (OCUL) Gains Following Updated on DEXTENZA NDA; FDA Says Corrective Action Address Most Issues Raised (NASDAQ:OCUL)
www.streetinsider.com - August 4 at 9:47 AM
News IconSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocular Therapeutix, Inc. – OCUL (NASDAQ:OCUL)
www.ssuchronicle.com - August 3 at 6:59 PM
News IconOcular Therapeutix to Report Second Quarter 2016 Financial Results (NASDAQ:OCUL)
www.cbs58.com - August 3 at 6:59 PM
twst.com logoOcular Therapeutix Inc.: Ocular Therapeutix™ to Report Second Quarter 2016 Financial Results (NASDAQ:OCUL)
www.twst.com - August 3 at 6:59 PM

Social

Ocular Therapeutix (NASDAQ:OCUL) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff